US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ESG Concept

3,676.97

+20.310.56%

Number of Gainers:28

Number of Losers:15

Number of Flat:- -

PE:- -

High:3,689.96

Open:3,643.33

Low:3,632.68

Close:3,656.66

Volume:302.92M

Turnover:61.67B

Market Cap:11.37T

Float Cap:11.16T

Loading ...

Salesforce Faces Copyright Lawsuit from Authors

BlackRock, Inc. Increases Total Voting Rights in Nordex SE to 4.22%

Texas Instruments Is Maintained at Hold by Stifel

Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

Benzinga_recent_news

Why Is Artiva Biotherapeutics Stock (ARTV) Up 105% Today?

1 Tech Stock to Buy Before the End of 2025

Press Release: Warner Bros. Veteran Jeffrey Schlesinger Joins Kartoon Studios Board of Directors

Zebra Technologies Chief Product & Solutions Officer Joseph R. White Resigns, Effective November 7, 2025

BRIEF-Vertex Announces Progress In Povetacicept Development Program And Presentation Of New Data At American Society Of Nephrology Kidney Week

Vertex Pharmaceuticals Announces Initiation of Pivotal Phase 2b/3 Trial for Povetacicept in Primary Membranous Nephropathy and Advances Biologics License Application for IgA Nephropathy

Vertex Pharmaceuticals Inc: Expects to Submit First Module to FDA for Potential Accelerated Approval Before End of 2025

THOMSON REUTERS

Vertex Pharmaceuticals Inc - FDA Grants Rolling Review for Povetacicept in Iga Nephropathy

THOMSON REUTERS

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

THOMSON REUTERS

Vertex Pharmaceuticals Inc: Remains on Track to Complete Full Bla Submission for Accelerated Approval in U.S. in First Half of 2026

THOMSON REUTERS

Salesforce: Hold Rating Amid AI Advancements and Market Challenges

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Deckers Outdoor Is Maintained at Market Perform by Telsey Advisory Group

Microsoft : Mizuho Raises Target Price to $640 From $625

THOMSON REUTERS

Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4567/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4567","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4567\",,,,,undefined,":{"symbol":"BK4567","market":"US","secType":"PLATE","nameCN":"ESG Concept","latestPrice":3676.9656,"timestamp":1760731199999,"preClose":3656.6567,"halted":0,"volume":302917635,"delay":0,"changeRate":0.005554,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":20.308838,"latestTime":"10-17 16:00:00 EDT","open":3643.3323,"high":3689.9585,"low":3632.68,"amount":61670495437.6839,"amplitude":0.015664,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":12.778861,"peRate":38.060962,"turnoverRate":0.00665,"increases":28,"decrements":15,"flats":0,"marketCap":11366657490256,"floatMarketCap":11162204264864},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4567\",,,,,undefined,":{"symbol":"BK4567","high":3689.9585,"amplitude":0.015664,"preClose":3656.6567,"low":3632.68,"pbRate":"12.778861","latestPrice":3676.9656,"volume":302917635,"delay":0,"open":3643.3323,"prevYearClose":3061.5488,"prevWeekClose":3641.2634,"prevMonthClose":3714.7412,"prevQuarterClose":3714.7412,"fiveDayClose":3641.2634,"twentyDayClose":3638.5173,"sixtyDayClose":3583.7136,"secType":"PLATE","market":"US","turnoverRate":0.00665,"peRate":38.060962,"marketCap":11366657490256,"floatMarketCap":11162204264864,"timestamp":1760731199999,"nameCN":"ESG Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4567\",,,,undefined,":{"bkCode":"BK4567","up":28,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4567\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1137784513","title":"Salesforce Faces Copyright Lawsuit from Authors","url":"https://stock-news.laohu8.com/highlight/detail?id=1137784513","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137784513?lang=en_us&edition=fundamental","pubTime":"2025-10-17 23:40","pubTimestamp":1760715633,"startTime":"0","endTime":"0","summary":"In early trading on Friday, Salesforce.com (CRM) saw a decline of 0.9%, as the company is currently facing a copyright lawsuit from authors. These authors allege that Salesforce used their books...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989764748.USD","LU0082616367.USD","LU0353189680.USD","LU2244417387.USD","BK4532","BK4585","LU1366333091.USD","LU2458330169.SGD","BK4550","LU1267930813.SGD","LU1551013342.USD","BK4598","LU1814569148.SGD","LU1551013425.SGD","LU1951200564.SGD","LU0234572021.USD","IE00BZ1G4Q59.USD","LU1988902786.USD","BK4534","IE00BQXX3D17.EUR","IE00BJTD4N35.SGD","CRM","LU2236285917.USD","BK4505","LU0251131958.USD","BK4527","LU2087625088.SGD","LU0980610538.SGD","LU1548497426.USD","LU1823568750.SGD","LU2357305700.SGD","LU0642271901.SGD","BK4579","LU0124676726.USD","LU2264538146.SGD","LU2756315664.SGD","LU1791710582.SGD","LU0289739343.SGD","LU0511384066.AUD","LU0187121727.USD","LU0719512351.SGD","LU0234570918.USD","LU0648001328.SGD","LU0742534661.SGD","LU0238689110.USD","LU2458330243.SGD","LU0820562030.AUD","LU0820561818.USD","LU0198837287.USD","BK4538","LU0157215616.USD","LU1267930490.SGD","IE00B19Z8X17.USD","LU0211327993.USD","BK4561","LU0109392836.USD","IE00BJTD4V19.USD","LU0127658192.USD","BK4023","LU0081259029.USD","LU1803068979.SGD","LU0528227936.USD","LU2286300806.USD","IE00B19Z9505.USD","LU0310799852.SGD","LU0289961442.SGD","LU2265009873.SGD","BK4543","LU0557290698.USD","BK4548","LU0130102774.USD","LU1316542783.SGD","IE00BQXX3F31.USD","LU0106261372.USD","LU1046421795.USD","BK4607","LU0354030511.USD","IE00B19Z8W00.USD","LU2361044865.SGD","LU0792757196.USD","LU0820561909.HKD","LU0006306889.USD","LU0211328371.USD","LU1923623000.USD","LU2247934214.USD","BK4613","LU1496350502.SGD","IE00BQXX3C00.GBP","BK4528","LU1496350171.SGD","LU0689472784.USD","BK4588","LU1064131342.USD","LU1989764664.SGD","LU0472753341.HKD","LU2361045086.USD","LU0353189763.USD","LU1791710400.SGD","LU0354030438.USD","IE00BKVL7J92.USD","LU1720051108.HKD","LU0251142724.SGD","LU0889565833.HKD","LU0057025933.USD","LU1201861249.SGD","LU1804176565.USD","LU0943347566.SGD","LU2461242641.AUD","BK4535","BK4608","BK4567","LU0069063385.USD","BK4581","LU0267386448.USD","LU0689626769.HKD","LU0889566641.SGD","LU1720051017.SGD","LU2361044949.HKD","LU0048573561.USD","LU2756315318.SGD","LU1951198990.SGD"],"gpt_icon":0},{"id":"2576054883","title":"BlackRock, Inc. Increases Total Voting Rights in Nordex SE to 4.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576054883","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576054883?lang=en_us&edition=fundamental","pubTime":"2025-10-17 23:01","pubTimestamp":1760713311,"startTime":"0","endTime":"0","summary":"BlackRock, Inc. has increased its total percentage of voting rights in Nordex SE from 4.14% to 4.22%, representing a rise of 0.08 percentage points compared to the previous holding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nordex SE published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on October 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDLc9TFTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670628061.USD","LU1599440770.SGD","LU0070302665.USD","LU2505996509.AUD","LU0742537680.HKD","LU0980610538.SGD","BK4504","LU1064131342.USD","LU0731783048.USD","LU1074936037.SGD","LU1291159041.SGD","LU0731783394.SGD","LU2264538146.SGD","LU1481011671.HKD","IE00BGHQF748.EUR","LU2430703178.SGD","BK4581","LU1989771016.USD","IE00BDGV0183.EUR","LU2430703251.USD","LU1509826696.USD","BK4534","LU1280957306.USD","IE00B64PRP62.GBP","LU2592432038.USD","BK4588","LU2505996681.GBP","BK4585","LU1481011911.USD","LU0130102774.USD","IE00BVYPNW00.USD","BK4535","LU0157215616.USD","LU1366333091.USD","LU0320765489.SGD","LU1670627923.USD","IE00BGHQF631.EUR","BK4135","LU1988902786.USD","IE00B42XCP33.USD","IE00BVYPNV92.GBP","BK4533","LU1201861249.SGD","LU2430703095.HKD","IE00B3PB1722.GBP","BLK","IE00B3QW5Z07.USD","BK4567","LU0648001328.SGD","LU0208291251.USD"],"gpt_icon":0},{"id":"2576516770","title":"Texas Instruments Is Maintained at Hold by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2576516770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576516770?lang=en_us&edition=fundamental","pubTime":"2025-10-17 22:47","pubTimestamp":1760712420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TXN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 17, 2025 10:47 ET (14:47 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0738911758.USD","IE00BFXG0V08.USD","LU0553294199.USD","IE00BZ199S13.USD","BK4604","BK4561","LU0347712357.USD","BK4605","LU1066053197.SGD","LU1983260115.SGD","LU2129689514.USD","LU2413666426.HKD","BK4512","BK4141","LU0868494617.USD","LU0312595415.SGD","LU0661504455.SGD","LU1244550221.USD","LU1003077747.HKD","LU0345774631.USD","LU0557290698.USD","LU1046421795.USD","LU1674673691.USD","LU2413666699.HKD","LU0234570918.USD","BK4554","BK4567","LU1244550577.SGD","SG9999003800.SGD","IE0008368304.USD","BK4127","BK4533","BK4581","BK4534","LU1823568750.SGD","BK4588","LU2129689431.USD","LU1721428933.USD","LU0949170772.SGD","LU0545562505.USD","LU1674673428.USD","LU1778281490.HKD","TXN","IE00BYQQ9H92.USD","SF","BK4585","IE0009356076.USD","SG9999011175.SGD","LU1228905540.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2576505698","title":"Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2576505698","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576505698?lang=en_us&edition=fundamental","pubTime":"2025-10-17 22:04","pubTimestamp":1760709840,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals plans by year-end to submit part of a license application to regulators for its kidney-disease treatment, and to have the full application submitted by first half of next year.The Boston biotechnology company said Friday that the decision came after the Food and Drug Administration granted a breakthrough-therapy designation to its investigational drug povetacicept for the treatment of IgA nephropathy.IgA nephropathy is a kidney disease caused by a buildup of a protein called IgA in the kidneys, which leads to inflammation and damage over time. Povetacicept treats IgA by helping to calm the immune system by blocking signals that make certain immune cells overactive.As part of the FDA's rolling review of the biologics license application, Vertex expects to submit the first module to the regulator for potential accelerated approval before the end of 2025, and said it remains on track to complete the full BLA submission for accelerated approval in the U.S. in the fir","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU1559883803.SGD","VERX","LU0889565916.HKD","BK4585","IE0009355771.USD","BK4139","IE00B894F039.SGD","LU1430594728.SGD","BK4588","LU0566484027.USD","LU1674673691.USD","LU0079474960.USD","LU0109394709.USD","LU1035775433.USD","SG9999001176.SGD","LU2324357040.USD","LU0061475181.USD","LU1585245621.USD","LU0757428866.USD","BK4023","IE00BZ9MQY76.HKD","LU0234570918.USD","LU2362541273.HKD","LU2456880835.USD","SG9999001176.USD","LU1093756168.USD","BK4567","IE0002270589.USD","IE00BJJMRZ35.SGD","LU2362541513.USD","IE00BFTCPJ56.SGD","BK4533","IE0002141913.USD","LU1093756325.SGD","LU2236285917.USD","LU0256863811.USD","SG9999013999.USD","BK4532","IE00B19Z9Z06.USD","LU1815336091.USD","SGXZ57979304.SGD","LU2462157665.USD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","LU0058720904.USD","VRTX","LU1778281490.HKD","LU0432979614.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2576505986","title":"FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times","url":"https://stock-news.laohu8.com/highlight/detail?id=2576505986","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576505986?lang=en_us&edition=fundamental","pubTime":"2025-10-17 22:03","pubTimestamp":1760709780,"startTime":"0","endTime":"0","summary":"The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/17/lab--Medical-Hospital-Research-Laborator.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/17/lab--Medical-Hospital-Research-Laborator.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/10/48275103/fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/10/48275103/fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0823434740.USD",".IXIC","LU0823434583.USD","LU2362541513.USD","QID","LU0882574055.USD","MNQmain","IE00B5TLWC47.USD","LU0823416689.USD","LU2237438978.USD","QLD","REGN","BK4585","LU0058720904.USD","LU2468319806.SGD","LU1917777945.USD","USJW.SI","LU0320765992.SGD","ACHV","LU1974910355.USD","FAST","BK4567","LU2089984988.USD","XLP","PSQ","IRON","LU0109394709.USD","SQQQ","BK4582","RVMD","LU2362540622.SGD","NQmain","EPP","IE00BYQQ9H92.USD","LU2106854487.HKD","USAW.SI","IE00BFXG0V08.USD","NVIW.SI","BK4007","IE00BFXG1179.USD","TSYW.SI","BK4139","BK4588","SNY","LU0053666078.USD","LU0889565916.HKD","LU2023250504.SGD","LU0289739699.SGD","TQQQ"],"gpt_icon":1},{"id":"2576905326","title":"Why Is Artiva Biotherapeutics Stock (ARTV) Up 105% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576905326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576905326?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:16","pubTimestamp":1760706984,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics stock saw major gains on Friday alongside a new Fast Track Designation from the FDA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-artiva-biotherapeutics-stock-artv-up-105-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-artiva-biotherapeutics-stock-artv-up-105-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","BK4585","BK4139","BK4567","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","BK4104","BK4588","FAST","IE00B5TLWC47.USD"],"gpt_icon":0},{"id":"2576534180","title":"1 Tech Stock to Buy Before the End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576534180","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576534180?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:15","pubTimestamp":1760706900,"startTime":"0","endTime":"0","summary":"Here's a less obvious chip stock to invest in amidst the AI boom.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F836959%2Fcomputer-chip.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F836959%2Fcomputer-chip.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/17/1-sector-stock-to-buy-before-the-end-of-2025/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/17/1-sector-stock-to-buy-before-the-end-of-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE0004445015.USD","LU0061475181.USD","LU1815336760.USD","LU2106854487.HKD","BK4588","LU1917777945.USD","IE00B7KXQ091.USD","LU0444971666.USD","BK4543","IE00BJJMRY28.SGD","LU2089985449.USD","LU1235294995.USD","LU0719512351.SGD","BK4567","BK4585","LU1815333072.USD","LU2023250504.SGD","LU1823568750.SGD","IE0009356076.USD","LU1069347547.HKD","BK4581","LU1642822529.SGD","IE00BN29S564.USD","LRCX","LU0957791311.USD","IE00BJJMRX11.SGD","IE00B4JS1V06.HKD","LU0081259029.USD","LU1670627923.USD","IE00BQXX3F31.USD","BK4533","IE0005OL40V9.USD","LU0957808578.USD","BK4147","IE00BFSS7M15.SGD","LU1035773651.USD","LU0274383776.USD","LU0444973449.USD","LU0096362180.USD","LU1366333091.USD","LU1046421795.USD","LU0157215616.USD","LU1670628061.USD","LU0348723411.USD","BK4551","LU0061474960.USD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","LU2931357623.SGD","LU0082616367.USD"],"gpt_icon":0},{"id":"2576005350","title":"Press Release: Warner Bros. Veteran Jeffrey Schlesinger Joins Kartoon Studios Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2576005350","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576005350?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:15","pubTimestamp":1760706900,"startTime":"0","endTime":"0","summary":"Former President of Warner Bros. Worldwide Television Distribution, and Global Distribution Leader Behind \"Friends,\" \"The Big Bang Theory,\" and \"Two and a Half Men\". Schlesinger Oversaw World's Largest Animation Catalogue Including Warner Bros., Hanna-Barbera, and MGM Animation. BEVERLY HILLS, Calif., Oct. 17, 2025  -- Kartoon Studios , a leading global producer and distributor of premium children's and family entertainment, today announced the appointment of Jeffrey Schlesinger -- former President of Warner Bros. Worldwide Television Distribution and one of the most accomplished executives in global media -- to its Board of Directors.Beyond the distribution of television series, Schlesinger oversaw the global rollout and monetization of the WB new releases and library feature films to all linear and non-linear outlets worldwide, including the Batman, Harry Potter, and The Lord of the Rings franchises.\"Kartoon Studios has assembled one of the most dynamic current portfolios of kids and","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTC.USD.CC","BK4585","BK4104","BTC.USD.HKCC","IE00B5TLWC47.USD","BK4567","FAST","IE00BFXG0V08.USD","BK4108","IE00BYQQ9H92.USD","BK4588","TOON"],"gpt_icon":0},{"id":"2576053356","title":"Zebra Technologies Chief Product & Solutions Officer Joseph R. White Resigns, Effective November 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576053356","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576053356?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:11","pubTimestamp":1760706660,"startTime":"0","endTime":"0","summary":"Zebra Technologies Corporation announced that Joseph R. White will resign from his position as Chief Product & Solutions Officer, effective November 7, 2025, to pursue another opportunity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zebra Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDLSd9xw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBRA","IE00BN0W2W23.USD","LU2211817866.USD","LU0390134368.USD","BK4157","BK4567","IE00BN0W2V16.EUR","BK4588","BK4585","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2576805804","title":"BRIEF-Vertex Announces Progress In Povetacicept Development Program And Presentation Of New Data At American Society Of Nephrology Kidney Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2576805804","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576805804?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:08","pubTimestamp":1760706511,"startTime":"0","endTime":"0","summary":"BRIEF-Vertex Announces Progress In Povetacicept Development Program And Presentation Of New Data At American Society Of Nephrology Kidney WeekOct 17 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:VERTE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA47XLBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0256863811.USD","LU0320765992.SGD","LU0889565916.HKD","LU2236285917.USD","LU0079474960.USD","VRTX","IE00BJJMRZ35.SGD","LU1035775433.USD","IE00B2B36J28.USD","IE0002141913.USD","LU0823416689.USD","LU1430594728.SGD","SGXZ57979304.SGD","LU2417539215.USD","LU0234570918.USD","IE00BJT1NW94.SGD","BK4588","IE00BZ9MQY76.HKD","LU0109394709.USD","LU2362541513.USD","LU1674673691.USD","IE0009355771.USD","LU2456880835.USD","LU1093756168.USD","LU1674673428.USD","BK4533","LU2462157665.USD","SG9999013999.USD","LU2362541273.HKD","LU1585245621.USD","IE00B19Z9Z06.USD","SG9999001176.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","LU2237438978.USD","BK4585","IE00B4R5TH58.HKD","LU1093756325.SGD","LU0417517546.SGD","LU0432979614.USD","LU0061475181.USD","BK4139","SG9999001176.SGD","IE00B19Z9P08.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4567","LU2362540622.SGD"],"gpt_icon":0},{"id":"2576224058","title":"Vertex Pharmaceuticals Announces Initiation of Pivotal Phase 2b/3 Trial for Povetacicept in Primary Membranous Nephropathy and Advances Biologics License Application for IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2576224058","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576224058?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:04","pubTimestamp":1760706263,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Announces Initiation of Pivotal Phase 2b/3 Trial for Povetacicept in Primary Membranous Nephropathy and Advances Biologics License Application for IgA Nephropathy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire  on October 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL3RSCvh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B19Z9Z06.USD","IE00B19Z3581.USD","BK4532","LU1674673691.USD","BK4585","LU0058720904.USD","LU0234570918.USD","LU1035775433.USD","IE00BZ9MQY76.HKD","LU0320765992.SGD","LU1430594728.SGD","LU1093756325.SGD","SG9999001176.USD","LU2324357040.USD","IE00B4R5TH58.HKD","LU0417517546.SGD","LU0823416689.USD","IE00B2B36J28.USD","LU1585245621.USD","IE0009355771.USD","BK4139","LU2456880835.USD","LU2462157665.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","SG9999013999.USD","BK4567","LU0256863811.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU2362541273.HKD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU2362541513.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","BK4533","IE0002141913.USD","LU2362540622.SGD","LU1093756168.USD","LU0432979614.USD","BK4588","VRTX","LU1069344957.HKD","LU2237438978.USD","LU2236285917.USD","LU1674673428.USD","LU0079474960.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2576067058","title":"Vertex Pharmaceuticals Inc: Expects to Submit First Module to FDA for Potential Accelerated Approval Before End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576067058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576067058?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:04","pubTimestamp":1760706240,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA47XLBB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4567","IE0002270589.USD","LU0432979614.USD","LU0109394709.USD","LU0823416689.USD","LU1093756168.USD","LU1093756325.SGD","LU1069344957.HKD","IE00B19Z9Z06.USD","LU2417539215.USD","SG9999001176.USD","LU2362540622.SGD","IE00BJJMRZ35.SGD","LU0256863811.USD","VRTX","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU2456880835.USD","SG9999001176.SGD","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","LU2236285917.USD","IE0009355771.USD","LU0889565916.HKD","BK4139","LU0061475181.USD","LU2362541513.USD","LU0417517546.SGD","LU1430594728.SGD","LU1674673691.USD","LU1585245621.USD","IE00BJT1NW94.SGD","LU1674673428.USD","LU2462157665.USD","LU0320765992.SGD","LU0234570918.USD","BK4532","IE0002141913.USD","IE00B2B36J28.USD","BK4585","LU2237438978.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU0289739699.SGD","LU0079474960.USD","IE00B19Z9P08.USD","SG9999013999.USD","BK4533","BK4588","LU1035775433.USD"],"gpt_icon":0},{"id":"2576058773","title":"Vertex Pharmaceuticals Inc - FDA Grants Rolling Review for Povetacicept in Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2576058773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576058773?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:04","pubTimestamp":1760706240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA47XLBB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999001176.USD","LU0417517546.SGD","IE0009355771.USD","LU1093756325.SGD","IE00B4R5TH58.HKD","LU0432979614.USD","LU0320765992.SGD","BK4567","BK4533","IE0002270589.USD","BK4585","LU2237438978.USD","LU1069344957.HKD","LU0109394709.USD","IE00B19Z9Z06.USD","LU0256863811.USD","LU0889565916.HKD","IE00B894F039.SGD","IE00B19Z3B42.SGD","LU1674673428.USD","VRTX","LU0058720904.USD","LU1035775433.USD","LU2362541513.USD","LU2362541273.HKD","IE00B19Z9P08.USD","IE00BZ9MQY76.HKD","SG9999001176.SGD","BK4139","LU0289739699.SGD","IE00BJT1NW94.SGD","BK4532","LU2324357040.USD","LU2362540622.SGD","LU2462157665.USD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","LU1778281490.HKD","IE00BJJMRZ35.SGD","LU0823416689.USD","LU2236285917.USD","LU0234570918.USD","LU1585245621.USD","LU2417539215.USD","SG9999013999.USD","BK4588","IE00B2B36J28.USD","LU1674673691.USD","LU2456880835.USD","IE0002141913.USD"],"gpt_icon":0},{"id":"2576058236","title":"Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2576058236","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576058236?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:04","pubTimestamp":1760706240,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA47XLBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0823416689.USD","IE00BZ9MQY76.HKD","SG9999001176.SGD","IE00BJJMRZ35.SGD","BK4533","BK4585","LU2362541513.USD","LU2362541273.HKD","IE00B19Z3B42.SGD","LU0061475181.USD","LU0234570918.USD","LU0256863811.USD","BK4567","LU2417539215.USD","LU1674673691.USD","LU1093756168.USD","LU2237438978.USD","LU1069344957.HKD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU0079474960.USD","SG9999013999.USD","SG9999001176.USD","LU1585245621.USD","LU1430594728.SGD","IE0009355771.USD","LU0432979614.USD","BK4139","IE00BJT1NW94.SGD","IE00B19Z9P08.USD","VRTX","LU2462157665.USD","LU1093756325.SGD","LU1035775433.USD","IE0002270589.USD","LU1674673428.USD","BK4532","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","BK4588","LU0109394709.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0417517546.SGD","LU2236285917.USD","LU2456880835.USD","LU0289739699.SGD","LU0320765992.SGD","LU2362540622.SGD"],"gpt_icon":0},{"id":"2576058062","title":"Vertex Pharmaceuticals Inc: Remains on Track to Complete Full Bla Submission for Accelerated Approval in U.S. in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2576058062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576058062?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:04","pubTimestamp":1760706240,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA47XLBB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0234570918.USD","LU2462157665.USD","LU1585245621.USD","SGXZ57979304.SGD","BK4588","IE0002141913.USD","IE00B4R5TH58.HKD","LU0823416689.USD","BK4533","IE00B2B36J28.USD","LU2456880835.USD","VRTX","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0256863811.USD","LU0417517546.SGD","LU0320765992.SGD","LU1093756168.USD","BK4585","IE0002270589.USD","IE00B19Z9Z06.USD","LU1093756325.SGD","LU2362541273.HKD","BK4532","LU2237438978.USD","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","LU2236285917.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU0289739699.SGD","LU1674673428.USD","LU0432979614.USD","LU2362541513.USD","BK4567","LU1674673691.USD","BK4139","SG9999013999.USD","IE00BZ9MQY76.HKD","LU0109394709.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","LU0061475181.USD","LU0079474960.USD","LU1035775433.USD","LU2417539215.USD","IE00BFTCPJ56.SGD","SG9999001176.USD","LU2362540622.SGD","SG9999001176.SGD"],"gpt_icon":0},{"id":"2576377860","title":"Salesforce: Hold Rating Amid AI Advancements and Market Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2576377860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576377860?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:17","pubTimestamp":1760703428,"startTime":"0","endTime":"0","summary":"Monness analyst Brian White has maintained their neutral stance on CRM stock, giving a Hold rating yesterday. Brian White has given his Hold rating...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/salesforce-hold-rating-amid-ai-advancements-and-market-challenges-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/salesforce-hold-rating-amid-ai-advancements-and-market-challenges-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4543","BK4538","LU1791710400.SGD","LU0889565833.HKD","LU1989764664.SGD","LU0820561909.HKD","LU0742534661.SGD","LU0289961442.SGD","IE00BKVL7J92.USD","LU2461242641.AUD","BK4505","LU1989764748.USD","LU0127658192.USD","LU0081259029.USD","BK4528","LU0106261372.USD","LU1366333091.USD","LU2265009873.SGD","LU2357305700.SGD","LU0069063385.USD","LU0198837287.USD","LU0528227936.USD","LU0006306889.USD","LU1720051108.HKD","LU0310799852.SGD","LU1814569148.SGD","LU2264538146.SGD","BK4535","LU1791710582.SGD","LU1923623000.USD","BK4534","IE00B19Z8W00.USD","LU0238689110.USD","LU0889566641.SGD","LU1267930490.SGD","LU0354030438.USD","LU2087625088.SGD","BK4581","LU0557290698.USD","BK4532","LU1548497426.USD","LU2756315664.SGD","LU1951200564.SGD","LU0689472784.USD","LU1316542783.SGD","LU0689626769.HKD","BK4567","LU2244417387.USD","LU0124676726.USD","CRM"],"gpt_icon":0},{"id":"2576059792","title":"Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population","url":"https://stock-news.laohu8.com/highlight/detail?id=2576059792","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576059792?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"After 5 years, Kisqali plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor demonstratin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168565/0/en/Novartis-Kisqali-5-year-NATALEE-data-demonstrate-28-reduction-in-risk-of-recurrence-in-the-broadest-early-breast-cancer-patient-population.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FUL","BK4211","BK4567","HR","OS","LU1721428933.USD","BK4109","LU2092937221.SGD","BK4203","BK4144","BK4581","IE00BN0W2V16.EUR","LU2413666699.HKD","LU2041044095.USD","LU1543694498.USD","LU2089279066.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2413666426.HKD","ET","BK4097","EBC","BK4561","BK4121","LU0347712357.USD","LU1165135440.EUR","BK4590","BK4588","A","BK4585","LU2229751404.USD","BK4225"],"gpt_icon":0},{"id":"2576032122","title":"Deckers Outdoor Is Maintained at Market Perform by Telsey Advisory Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2576032122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576032122?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DECK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 17, 2025 08:00 ET (12:00 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","DECK","BK4585","BK4567","LU0266013472.USD","BK4146"],"gpt_icon":0},{"id":"2576803498","title":"Microsoft : Mizuho Raises Target Price to $640 From $625","url":"https://stock-news.laohu8.com/highlight/detail?id=2576803498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576803498?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:30","pubTimestamp":1760700639,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nFWN3VY2AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097344431.USD","LU1814569148.SGD","LU1674673691.USD","IE00BFSS7M15.SGD","LU2456880835.USD","LU1564329461.SGD","LU0354030511.USD","LU1804176565.USD","BK4567","LU2097344357.USD","LU2023250330.USD","BK4585","IE000W1ABFV2.USD","LU1564329115.USD","LU2746668974.SGD","LU0072461881.USD","LU0323591593.USD","IE0009356076.USD","IE00B3SWFQ91.USD","LU0820561909.HKD","LU0354030438.USD","LU2089284900.SGD","LU1861127337.USD","LU0198837287.USD","MSFT","LU1188199696.SGD","LU2746668461.USD","LU1674673428.USD","IE00BDCRKT87.USD","SG9999001077.SGD","LU0957808578.USD","LU1116320737.USD","LU1564329628.SGD","LU0048584097.USD","BK4566","LU0689472784.USD","LU0965509283.SGD","LU1803068979.SGD","IE00B19Z8W00.USD","IE00BJJMRY28.SGD","LU1582986433.USD","LU0256863902.USD","LU1066051811.HKD","LU0965508806.USD","LU2264538146.SGD","LU0029864427.USD","LU1366192091.USD","IE00BMPRXN33.USD","LU1121112475.USD","LU1119994496.HKD"],"gpt_icon":0},{"id":"2576036299","title":"Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2576036299","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576036299?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:17","pubTimestamp":1760696220,"startTime":"0","endTime":"0","summary":"Is there a glimmer of hope for either of these underperforming healthcare companies?","market":"nz","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837832%2Fdoctor-and-patient-in-a-hospital-room.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837832%2Fdoctor-and-patient-in-a-hospital-room.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/17/better-beaten-down-stock-iovance-teladoc/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/17/better-beaten-down-stock-iovance-teladoc/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4534","BK4167","BK4504","BK4585","BK4548","LU1861558580.USD","BK4567","TDOC","LU1861559042.SGD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":35,"pageCount":2,"totalSize":687,"code":"91000000","status":"200"}]}}